Patient Reported Outcomes/Metrics Program Trial
Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jul 19, 2021
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The Patient Reported Outcomes/Metrics Program Trial is a study designed to see if it is possible to recruit 100 patients who are receiving radiotherapy (RT) for metastatic cancer, which means their cancer has spread to other parts of the body. The study aims to explore whether a special shirt called Hexoskin can help monitor and identify side effects related to radiotherapy early on. This trial is currently recruiting participants aged between 65 and 74, and it is open to all genders.
To be eligible for this study, participants must be scheduled to receive palliative radiotherapy for pain relief and have a known cancer diagnosis. They should also be able to wear the Hexoskin shirt and use a mobile app called Zamplo, which helps track their health information. Participants will need to fill out questionnaires and share details about their pain relief medications. It’s important to note that individuals who are pregnant, have certain medical devices like pacemakers, or have major cognitive issues are not eligible to join the trial. If you choose to participate, you can expect to wear the shirt and use the app to help healthcare providers understand your treatment experience better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Planned to receive palliative radiotherapy for pain
- • Known cancer diagnosis
- • Able to wear Hexoskin Medical Shirt
- • Ability to use and populate the mobile app (Zamplo) with or without assistance
- • ECOG: 0-3
- • Willing to provide a list of analgesic (pain relief) medication
- • Willing to complete questionnaires
- • Life expectancy of at least 3 months
- Exclusion Criteria:
- • Receiving whole brain radiotherapy
- • Major cognitive or psychiatric impairments
- • Pregnant women
- • Allergies to: polyester, synthetic fibers
- • Patients with pacemakers or implantable cardioverter-defibrillator (ICD)
- • Patients on a Holter Monitor
About University Health Network, Toronto
University Health Network (UHN), based in Toronto, is a leading academic health sciences center dedicated to advancing patient care through innovative research and education. As a prominent sponsor of clinical trials, UHN integrates cutting-edge scientific discoveries with clinical practice, facilitating the development of new therapies and treatment modalities. With a commitment to improving health outcomes, UHN collaborates with a diverse network of researchers, healthcare professionals, and industry partners, fostering an environment that prioritizes patient safety and ethical standards in clinical research. Through its extensive resources and expertise, UHN plays a pivotal role in transforming healthcare and enhancing the quality of life for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Philip Wong
Principal Investigator
The Princess Margaret Cancer Foundation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials